Supernus Pharmaceuticals | SUPN - Sales Revenues


Supernus Pharmaceuticals reported $219.1M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Abbott USD 13.01B 423M Sep/2026
ANI Pharmaceuticals USD 266M 28.5M Jun/2026
Aurora Cannabis CAD 38.01M 56.18M Mar/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Canopy Growth CAD 71.25M 3.29M Mar/2026
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 256.15M 91.25M Jun/2026
Eisai JPY 234.33B 28.9B Jun/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Novo Nordisk DKK 78.49B 18.33B Jun/2026
Pacira USD 192.4M 15.4M Jun/2026
Perrigo USD 1.02B 51M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Supernus Pharmaceuticals USD 219.1M 11.39M Jun/2026
United Therapeutics USD 783.3M 1.8M Jun/2026
Xeris Pharmaceuticals USD 83.13M 2.68M Mar/2026